Repros under selling pressure as key Ad Comm meeting approaches

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Shares of micro cap Repros Therapeutics (RPRX -14.6%) drop on a 4x surge in volume. Investors appear anxious over the upcoming September 17 joint meeting of the FDA's Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.

Two controversial issues regarding testosterone replacement therapy (TRT) are on the agenda: the appropriate patient population for whom TRT should be indicated and the potential risk of major adverse cardiovascular events associated with TRT use.

Repros' lead product is Androxal, an oral testosterone replacement therapy for secondary hypogonadism.

RPRX rallied last week in response to successful Phase 3 results for Androxal compared to AbbVie's (ABBV -0.1%) Androgel.

Briefing docs